HANNAH BRADLEY: Open Payments
NPI 1033865654 · LA MESA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,713 in 87 payments from 23 companies in 2025. Trend: 2023 $1,733 · 2024 $2,484 · 2025 $1,713
Food & beverage: $1,713
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $262 |
| UCB, Inc. | 15 | $225 |
| Janssen Pharmaceuticals, Inc | 4 | $155 |
| Neurelis, Inc. | 13 | $149 |
| Neurocrine BioSciences, Inc. | 4 | $95 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $90 |
| Soleno Therapeutics, Inc. | 4 | $80 |
| Axsome Therapeutics, Inc. | 3 | $78 |
| Indivior Inc. | 3 | $77 |
| Amgen Inc. | 3 | $58 |
Products named: SPRAVATO, VALTOCO, VRAYLAR, Fintepla, INGREZZA, CAPLYTA, REXULTI, Briviact.
Industry payments across CA — which companies pay providers there.
